David Brown
Concepts (564)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Reperfusion Injury | 21 | 2021 | 137 | 4.330 |
Why?
| | Mitochondria, Heart | 11 | 2020 | 101 | 1.820 |
Why?
| | Neurons | 10 | 2020 | 1637 | 1.430 |
Why?
| | Oligopeptides | 8 | 2024 | 266 | 1.300 |
Why?
| | KCNQ2 Potassium Channel | 4 | 2013 | 15 | 1.290 |
Why?
| | Action Potentials | 11 | 2019 | 501 | 1.210 |
Why?
| | Physical Conditioning, Animal | 8 | 2013 | 241 | 1.170 |
Why?
| | Locomotion | 5 | 2015 | 101 | 1.130 |
Why?
| | Myocardial Infarction | 10 | 2021 | 1209 | 1.080 |
Why?
| | Myocardium | 12 | 2020 | 927 | 1.010 |
Why?
| | Mitochondria | 7 | 2021 | 981 | 1.000 |
Why?
| | Adaptation, Physiological | 6 | 2011 | 566 | 0.930 |
Why?
| | Rats, Sprague-Dawley | 27 | 2020 | 2512 | 0.920 |
Why?
| | Rats | 33 | 2021 | 5553 | 0.900 |
Why?
| | Ion Channels | 2 | 2020 | 129 | 0.900 |
Why?
| | Reactive Oxygen Species | 6 | 2021 | 601 | 0.890 |
Why?
| | Energy Metabolism | 5 | 2021 | 925 | 0.880 |
Why?
| | Potassium Channel Blockers | 6 | 2013 | 47 | 0.790 |
Why?
| | Robotics | 1 | 2024 | 86 | 0.780 |
Why?
| | Transducers | 3 | 2012 | 26 | 0.770 |
Why?
| | Acoustics | 3 | 2012 | 48 | 0.760 |
Why?
| | Potassium Channels | 5 | 2010 | 145 | 0.750 |
Why?
| | Receptors, Purinergic P2 | 3 | 2010 | 23 | 0.750 |
Why?
| | Arrhythmias, Cardiac | 4 | 2016 | 355 | 0.740 |
Why?
| | Reperfusion Injury | 5 | 2014 | 295 | 0.740 |
Why?
| | Calcium | 13 | 2019 | 1174 | 0.730 |
Why?
| | KCNQ Potassium Channels | 3 | 2019 | 4 | 0.710 |
Why?
| | Walking | 3 | 2024 | 542 | 0.700 |
Why?
| | Exercise Test | 6 | 2024 | 626 | 0.690 |
Why?
| | Animals | 56 | 2021 | 37800 | 0.680 |
Why?
| | NADH Dehydrogenase | 1 | 2021 | 20 | 0.670 |
Why?
| | Stroke | 6 | 2015 | 1259 | 0.660 |
Why?
| | Pyramidal Cells | 3 | 2019 | 79 | 0.630 |
Why?
| | Pharmacology | 1 | 2020 | 11 | 0.620 |
Why?
| | Myocytes, Cardiac | 5 | 2016 | 538 | 0.620 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 4 | 2007 | 33 | 0.610 |
Why?
| | Muscle, Skeletal | 8 | 2011 | 1784 | 0.600 |
Why?
| | Amino Acids, Dicarboxylic | 1 | 2019 | 9 | 0.590 |
Why?
| | Mitochondrial Membrane Transport Proteins | 3 | 2017 | 46 | 0.590 |
Why?
| | Prolyl-Hydroxylase Inhibitors | 1 | 2019 | 6 | 0.590 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2011 | 66 | 0.590 |
Why?
| | Psychomotor Performance | 3 | 2011 | 328 | 0.580 |
Why?
| | Brain Injuries | 1 | 2024 | 506 | 0.580 |
Why?
| | Mitochondrial Membranes | 3 | 2020 | 40 | 0.570 |
Why?
| | Glutathione | 4 | 2016 | 364 | 0.570 |
Why?
| | Potassium Channels, Inwardly Rectifying | 4 | 2006 | 44 | 0.550 |
Why?
| | Exercise Therapy | 3 | 2016 | 474 | 0.540 |
Why?
| | Surgical Flaps | 1 | 2019 | 142 | 0.530 |
Why?
| | Mitochondria, Liver | 2 | 2017 | 70 | 0.520 |
Why?
| | Cardiolipins | 6 | 2020 | 83 | 0.500 |
Why?
| | KCNQ1 Potassium Channel | 2 | 2018 | 8 | 0.490 |
Why?
| | Propranolol | 1 | 2016 | 44 | 0.480 |
Why?
| | Glutathione Reductase | 2 | 2013 | 24 | 0.470 |
Why?
| | Burns | 2 | 2023 | 369 | 0.470 |
Why?
| | Patch-Clamp Techniques | 9 | 2013 | 289 | 0.460 |
Why?
| | Sarcolemma | 2 | 2006 | 35 | 0.460 |
Why?
| | Guinea Pigs | 3 | 2013 | 159 | 0.450 |
Why?
| | Stroke Rehabilitation | 5 | 2011 | 43 | 0.450 |
Why?
| | Nandrolone | 1 | 2014 | 3 | 0.420 |
Why?
| | Adenosine Triphosphate | 4 | 2021 | 500 | 0.420 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2014 | 11 | 0.420 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 25 | 0.420 |
Why?
| | Mitochondrial Myopathies | 2 | 2024 | 10 | 0.420 |
Why?
| | Heart | 7 | 2020 | 625 | 0.410 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 38 | 0.410 |
Why?
| | Skin | 3 | 2023 | 751 | 0.410 |
Why?
| | Physical Exertion | 3 | 2016 | 205 | 0.410 |
Why?
| | Postural Balance | 2 | 2021 | 240 | 0.400 |
Why?
| | Apoptosis | 3 | 2021 | 2395 | 0.400 |
Why?
| | Bradykinin | 3 | 2010 | 48 | 0.390 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2014 | 68 | 0.390 |
Why?
| | Pain Management | 2 | 2010 | 407 | 0.390 |
Why?
| | Membrane Lipids | 1 | 2013 | 82 | 0.380 |
Why?
| | Leg | 3 | 2011 | 239 | 0.370 |
Why?
| | In Vitro Techniques | 7 | 2016 | 1041 | 0.370 |
Why?
| | Sound | 1 | 2012 | 55 | 0.370 |
Why?
| | NADPH Oxidases | 1 | 2013 | 120 | 0.370 |
Why?
| | Receptors, Muscarinic | 4 | 2007 | 20 | 0.370 |
Why?
| | Cardiotonic Agents | 3 | 2020 | 94 | 0.360 |
Why?
| | Extremities | 2 | 2011 | 140 | 0.360 |
Why?
| | Time Factors | 10 | 2016 | 7128 | 0.360 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2011 | 6 | 0.360 |
Why?
| | Male | 43 | 2024 | 72263 | 0.350 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 590 | 0.350 |
Why?
| | Keratinocytes | 1 | 2013 | 250 | 0.350 |
Why?
| | Water | 2 | 2012 | 465 | 0.350 |
Why?
| | Pain | 2 | 2010 | 781 | 0.340 |
Why?
| | Anesthetics, Combined | 1 | 2011 | 7 | 0.340 |
Why?
| | Motor Activity | 3 | 2011 | 723 | 0.340 |
Why?
| | Xylazine | 1 | 2011 | 15 | 0.340 |
Why?
| | Animals, Laboratory | 1 | 2011 | 21 | 0.340 |
Why?
| | Myocardial Ischemia | 5 | 2020 | 284 | 0.340 |
Why?
| | Up-Regulation | 5 | 2018 | 847 | 0.340 |
Why?
| | Synapses | 3 | 2019 | 435 | 0.340 |
Why?
| | Th17 Cells | 1 | 2011 | 100 | 0.330 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 181 | 0.320 |
Why?
| | Axons | 2 | 2011 | 202 | 0.320 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2010 | 37 | 0.310 |
Why?
| | Anesthetics | 1 | 2011 | 99 | 0.310 |
Why?
| | Cytoskeletal Proteins | 1 | 2010 | 155 | 0.310 |
Why?
| | Ketamine | 1 | 2011 | 133 | 0.300 |
Why?
| | Biomechanical Phenomena | 4 | 2024 | 845 | 0.300 |
Why?
| | Cells, Cultured | 10 | 2018 | 4102 | 0.290 |
Why?
| | Myocardial Contraction | 3 | 2020 | 287 | 0.290 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2011 | 388 | 0.280 |
Why?
| | Absorbable Implants | 1 | 2009 | 37 | 0.280 |
Why?
| | Physical Therapists | 2 | 2021 | 64 | 0.280 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2006 | 118 | 0.280 |
Why?
| | Convulsants | 1 | 2008 | 8 | 0.280 |
Why?
| | Arterial Occlusive Diseases | 1 | 2009 | 89 | 0.280 |
Why?
| | Benzodiazepinones | 1 | 2008 | 18 | 0.270 |
Why?
| | Dendritic Cells | 1 | 2011 | 496 | 0.270 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 170 | 0.270 |
Why?
| | Blood Vessel Prosthesis | 1 | 2009 | 140 | 0.270 |
Why?
| | Genetic Diseases, Inborn | 1 | 2008 | 44 | 0.270 |
Why?
| | Superior Cervical Ganglion | 4 | 2013 | 5 | 0.260 |
Why?
| | Calcium Signaling | 2 | 2012 | 243 | 0.260 |
Why?
| | KCNQ3 Potassium Channel | 1 | 2007 | 3 | 0.260 |
Why?
| | Electromyography | 5 | 2015 | 415 | 0.260 |
Why?
| | Hippocalcin | 1 | 2007 | 1 | 0.260 |
Why?
| | Nerve Degeneration | 1 | 2007 | 48 | 0.260 |
Why?
| | Exercise | 2 | 2011 | 2183 | 0.250 |
Why?
| | Coronary Circulation | 3 | 2021 | 133 | 0.250 |
Why?
| | Humans | 42 | 2024 | 144298 | 0.250 |
Why?
| | Membrane Proteins | 1 | 2013 | 1158 | 0.250 |
Why?
| | Phenylenediamines | 3 | 2013 | 12 | 0.250 |
Why?
| | Calcium Channels | 2 | 2010 | 155 | 0.240 |
Why?
| | Vibration | 3 | 2012 | 71 | 0.240 |
Why?
| | Carbamates | 3 | 2013 | 51 | 0.240 |
Why?
| | Hydroxamic Acids | 1 | 2006 | 94 | 0.230 |
Why?
| | Prosencephalon | 1 | 2006 | 53 | 0.230 |
Why?
| | Female | 32 | 2024 | 78137 | 0.230 |
Why?
| | Hydrolases | 1 | 2006 | 55 | 0.230 |
Why?
| | Phospholipids | 2 | 2017 | 214 | 0.230 |
Why?
| | Stents | 2 | 2013 | 557 | 0.230 |
Why?
| | Posture | 2 | 2021 | 197 | 0.220 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2019 | 119 | 0.220 |
Why?
| | Acetylcholine | 1 | 2006 | 208 | 0.220 |
Why?
| | Organometallic Compounds | 1 | 2006 | 112 | 0.220 |
Why?
| | Oxidation-Reduction | 4 | 2013 | 1073 | 0.220 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2007 | 231 | 0.220 |
Why?
| | Bicycling | 2 | 2005 | 116 | 0.210 |
Why?
| | Sodium | 3 | 2020 | 195 | 0.210 |
Why?
| | Parotid Gland | 1 | 2004 | 17 | 0.210 |
Why?
| | Linoleic Acid | 2 | 2017 | 44 | 0.210 |
Why?
| | Protein Structure, Tertiary | 2 | 2008 | 847 | 0.210 |
Why?
| | Stress, Physiological | 1 | 2007 | 446 | 0.210 |
Why?
| | KATP Channels | 3 | 2011 | 23 | 0.210 |
Why?
| | Glutamic Acid | 1 | 2006 | 254 | 0.200 |
Why?
| | Cyclic AMP | 1 | 2004 | 205 | 0.200 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1055 | 0.200 |
Why?
| | Zinc | 1 | 2006 | 295 | 0.190 |
Why?
| | Models, Animal | 3 | 2011 | 388 | 0.190 |
Why?
| | Tissue Engineering | 1 | 2007 | 441 | 0.190 |
Why?
| | Cicatrix | 1 | 2023 | 69 | 0.190 |
Why?
| | Neurons, Afferent | 1 | 2003 | 102 | 0.190 |
Why?
| | Skin Transplantation | 2 | 2023 | 85 | 0.190 |
Why?
| | Sex Characteristics | 2 | 2006 | 776 | 0.190 |
Why?
| | Physical Examination | 2 | 2021 | 240 | 0.190 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 819 | 0.190 |
Why?
| | Receptors, Bradykinin | 1 | 2002 | 5 | 0.180 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2002 | 20 | 0.180 |
Why?
| | Anaphylaxis | 1 | 2023 | 102 | 0.180 |
Why?
| | Middle Aged | 12 | 2024 | 35892 | 0.180 |
Why?
| | Movement | 2 | 2021 | 295 | 0.180 |
Why?
| | Mutation | 3 | 2013 | 4068 | 0.170 |
Why?
| | Oxygen Consumption | 3 | 2021 | 715 | 0.170 |
Why?
| | Equipment Design | 3 | 2012 | 522 | 0.170 |
Why?
| | Body Weight | 4 | 2013 | 968 | 0.170 |
Why?
| | Aged | 10 | 2024 | 25901 | 0.170 |
Why?
| | Genotype | 2 | 2024 | 1843 | 0.170 |
Why?
| | Coronary Occlusion | 1 | 2021 | 20 | 0.170 |
Why?
| | Leigh Disease | 1 | 2020 | 22 | 0.160 |
Why?
| | Rhabdomyolysis | 1 | 2020 | 24 | 0.160 |
Why?
| | Titanium | 2 | 2019 | 76 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4525 | 0.160 |
Why?
| | Acidosis, Lactic | 1 | 2020 | 45 | 0.160 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 204 | 0.160 |
Why?
| | Gene Expression | 3 | 2015 | 1474 | 0.160 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2019 | 74 | 0.150 |
Why?
| | Rabbits | 2 | 2013 | 646 | 0.150 |
Why?
| | Isolated Heart Preparation | 2 | 2017 | 6 | 0.150 |
Why?
| | Neurotransmitter Agents | 1 | 2020 | 82 | 0.150 |
Why?
| | CRISPR-Cas Systems | 1 | 2021 | 167 | 0.150 |
Why?
| | Rats, Hairless | 1 | 2019 | 1 | 0.150 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2019 | 12 | 0.150 |
Why?
| | Ischemia | 2 | 2021 | 421 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2008 | 392 | 0.150 |
Why?
| | Anthracenes | 2 | 2013 | 31 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2013 | 2012 | 0.150 |
Why?
| | Mitochondrial Diseases | 1 | 2020 | 92 | 0.150 |
Why?
| | Cell Membrane | 3 | 2008 | 704 | 0.140 |
Why?
| | Glycolysis | 1 | 2021 | 340 | 0.140 |
Why?
| | Dendrites | 2 | 2011 | 104 | 0.140 |
Why?
| | RNA, Messenger | 5 | 2018 | 2808 | 0.140 |
Why?
| | Nasal Septum | 1 | 2019 | 30 | 0.140 |
Why?
| | Nasal Obstruction | 1 | 2019 | 26 | 0.140 |
Why?
| | Proteolipids | 1 | 2018 | 28 | 0.140 |
Why?
| | Unilamellar Liposomes | 1 | 2018 | 8 | 0.140 |
Why?
| | Ischemic Preconditioning | 1 | 2019 | 47 | 0.140 |
Why?
| | Membrane Microdomains | 1 | 2018 | 34 | 0.140 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.140 |
Why?
| | Models, Anatomic | 1 | 2019 | 87 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2021 | 743 | 0.140 |
Why?
| | HEK293 Cells | 1 | 2021 | 741 | 0.140 |
Why?
| | Rhinoplasty | 1 | 2019 | 39 | 0.140 |
Why?
| | Ventricular Function, Left | 4 | 2016 | 535 | 0.140 |
Why?
| | Presynaptic Terminals | 1 | 2019 | 89 | 0.140 |
Why?
| | Hydrolysis | 2 | 2010 | 197 | 0.140 |
Why?
| | Cleft Lip | 1 | 2019 | 72 | 0.140 |
Why?
| | Mice | 8 | 2019 | 18218 | 0.140 |
Why?
| | Receptors, Purinergic P2Y1 | 2 | 2010 | 8 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 243 | 0.140 |
Why?
| | Citrate (si)-Synthase | 3 | 2009 | 53 | 0.130 |
Why?
| | Cleft Palate | 1 | 2019 | 89 | 0.130 |
Why?
| | Vitiligo | 1 | 2017 | 42 | 0.130 |
Why?
| | Movement Disorders | 1 | 2018 | 70 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 257 | 0.130 |
Why?
| | Docosahexaenoic Acids | 1 | 2017 | 83 | 0.130 |
Why?
| | Receptor, Bradykinin B2 | 2 | 2010 | 4 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 971 | 0.130 |
Why?
| | Oxidative Stress | 2 | 2016 | 1331 | 0.120 |
Why?
| | Synaptic Transmission | 1 | 2019 | 292 | 0.120 |
Why?
| | Adult | 9 | 2024 | 40408 | 0.120 |
Why?
| | Ganglia, Spinal | 2 | 2010 | 89 | 0.120 |
Why?
| | Transfection | 3 | 2010 | 922 | 0.120 |
Why?
| | Physical Therapy Modalities | 2 | 2018 | 334 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 41 | 0.120 |
Why?
| | Signal Transduction | 4 | 2019 | 5182 | 0.120 |
Why?
| | Kynurenine 3-Monooxygenase | 1 | 2015 | 4 | 0.110 |
Why?
| | Bradycardia | 1 | 2016 | 61 | 0.110 |
Why?
| | Inflammation | 1 | 2007 | 2862 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2017 | 261 | 0.110 |
Why?
| | CHO Cells | 2 | 2007 | 165 | 0.110 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 48 | 0.110 |
Why?
| | Sodium-Calcium Exchanger | 3 | 2020 | 13 | 0.110 |
Why?
| | Type C Phospholipases | 3 | 2005 | 69 | 0.110 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2018 | 269 | 0.110 |
Why?
| | Cricetinae | 2 | 2007 | 296 | 0.110 |
Why?
| | Environmental Exposure | 1 | 2019 | 573 | 0.110 |
Why?
| | Hypotension | 1 | 2016 | 126 | 0.110 |
Why?
| | Membrane Potentials | 2 | 2018 | 278 | 0.110 |
Why?
| | Running | 2 | 2016 | 230 | 0.110 |
Why?
| | Motion | 2 | 2012 | 99 | 0.110 |
Why?
| | Benzamides | 2 | 2006 | 224 | 0.110 |
Why?
| | Kynurenine | 1 | 2015 | 103 | 0.110 |
Why?
| | Particulate Matter | 1 | 2017 | 336 | 0.110 |
Why?
| | Mice, Inbred C57BL | 4 | 2018 | 5954 | 0.110 |
Why?
| | Neural Inhibition | 2 | 2006 | 178 | 0.100 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 268 | 0.100 |
Why?
| | Disease Susceptibility | 3 | 2019 | 342 | 0.100 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2020 | 154 | 0.100 |
Why?
| | Tetraethylammonium | 1 | 2013 | 16 | 0.100 |
Why?
| | Free Radical Scavengers | 1 | 2013 | 82 | 0.100 |
Why?
| | Coronary Vessels | 2 | 2016 | 246 | 0.100 |
Why?
| | Estrous Cycle | 1 | 2013 | 22 | 0.100 |
Why?
| | Rodent Diseases | 1 | 2013 | 28 | 0.100 |
Why?
| | Monoterpenes | 1 | 2013 | 16 | 0.100 |
Why?
| | No-Reflow Phenomenon | 1 | 2013 | 7 | 0.100 |
Why?
| | Computer Simulation | 2 | 2008 | 1017 | 0.100 |
Why?
| | Kinetics | 2 | 2010 | 1603 | 0.100 |
Why?
| | Paresis | 2 | 2011 | 30 | 0.100 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 150 | 0.100 |
Why?
| | TRPV Cation Channels | 1 | 2013 | 43 | 0.090 |
Why?
| | Ceramics | 1 | 2012 | 22 | 0.090 |
Why?
| | GTP-Binding Proteins | 2 | 2004 | 153 | 0.090 |
Why?
| | Appetite | 1 | 2013 | 71 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 572 | 0.090 |
Why?
| | Mitochondrial ADP, ATP Translocases | 1 | 2012 | 2 | 0.090 |
Why?
| | Nanotubes, Carbon | 1 | 2012 | 46 | 0.090 |
Why?
| | Protein Isoforms | 2 | 2005 | 393 | 0.090 |
Why?
| | Superoxide Dismutase | 2 | 2005 | 300 | 0.090 |
Why?
| | Glutathione Disulfide | 1 | 2012 | 32 | 0.090 |
Why?
| | Minocycline | 1 | 2012 | 22 | 0.090 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2011 | 7 | 0.090 |
Why?
| | Protein Kinase C | 2 | 2004 | 249 | 0.090 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 144 | 0.090 |
Why?
| | Pressure | 1 | 2012 | 224 | 0.090 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2012 | 151 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 849 | 0.090 |
Why?
| | Macrophages | 1 | 2019 | 1496 | 0.090 |
Why?
| | Glutathione Peroxidase | 1 | 2011 | 39 | 0.090 |
Why?
| | Permeability | 1 | 2012 | 168 | 0.090 |
Why?
| | Models, Biological | 2 | 2010 | 1807 | 0.090 |
Why?
| | Calcium Channel Blockers | 1 | 2012 | 165 | 0.080 |
Why?
| | Electricity | 1 | 2011 | 26 | 0.080 |
Why?
| | Peptides | 1 | 2016 | 985 | 0.080 |
Why?
| | Cyclosporine | 1 | 2012 | 255 | 0.080 |
Why?
| | Receptor, Metabotropic Glutamate 5 | 1 | 2010 | 5 | 0.080 |
Why?
| | Tissue and Organ Harvesting | 1 | 2011 | 75 | 0.080 |
Why?
| | Cardiac Glycosides | 1 | 2010 | 1 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3180 | 0.080 |
Why?
| | Calcium Channels, N-Type | 1 | 2010 | 12 | 0.080 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 2010 | 22 | 0.080 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 19 | 0.080 |
Why?
| | Muscarinic Agonists | 2 | 2007 | 14 | 0.080 |
Why?
| | Hemodynamics | 2 | 2013 | 1113 | 0.080 |
Why?
| | Nociceptors | 1 | 2010 | 40 | 0.080 |
Why?
| | Ions | 1 | 2010 | 68 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2013 | 2177 | 0.080 |
Why?
| | Models, Theoretical | 2 | 2011 | 574 | 0.080 |
Why?
| | Bone Nails | 1 | 2010 | 61 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2011 | 308 | 0.080 |
Why?
| | Astrocytes | 1 | 2011 | 228 | 0.080 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2009 | 17 | 0.080 |
Why?
| | Sulfhydryl Compounds | 1 | 2011 | 187 | 0.070 |
Why?
| | Femoral Fractures | 1 | 2010 | 82 | 0.070 |
Why?
| | Oxygen | 2 | 2021 | 978 | 0.070 |
Why?
| | Regional Blood Flow | 1 | 2011 | 513 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2013 | 1739 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2023 | 17104 | 0.070 |
Why?
| | Ankyrins | 1 | 2008 | 12 | 0.070 |
Why?
| | Rats, Inbred Strains | 1 | 2008 | 320 | 0.070 |
Why?
| | Recovery of Function | 2 | 2009 | 715 | 0.070 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 2 | 2005 | 10 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2013 | 3106 | 0.070 |
Why?
| | Transcortin | 1 | 2007 | 14 | 0.070 |
Why?
| | Basal Ganglia | 1 | 2008 | 57 | 0.070 |
Why?
| | Phenolsulfonphthalein | 1 | 2007 | 1 | 0.070 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2007 | 31 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 663 | 0.070 |
Why?
| | Hepatocyte Growth Factor | 1 | 2007 | 33 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2007 | 888 | 0.070 |
Why?
| | Bicarbonates | 1 | 2007 | 45 | 0.060 |
Why?
| | Freund's Adjuvant | 1 | 2007 | 18 | 0.060 |
Why?
| | Finite Element Analysis | 1 | 2007 | 67 | 0.060 |
Why?
| | Muscarine | 1 | 2007 | 3 | 0.060 |
Why?
| | Thapsigargin | 1 | 2007 | 20 | 0.060 |
Why?
| | Protein Subunits | 1 | 2008 | 228 | 0.060 |
Why?
| | Adrenal Glands | 1 | 2007 | 76 | 0.060 |
Why?
| | Fluoresceins | 1 | 2007 | 48 | 0.060 |
Why?
| | Hypertrophy | 1 | 2007 | 128 | 0.060 |
Why?
| | Coloring Agents | 1 | 2007 | 91 | 0.060 |
Why?
| | Ranidae | 1 | 2007 | 14 | 0.060 |
Why?
| | Chemokine CXCL12 | 1 | 2007 | 86 | 0.060 |
Why?
| | Phosphatidylethanolamines | 2 | 2017 | 76 | 0.060 |
Why?
| | Diffusion | 1 | 2007 | 122 | 0.060 |
Why?
| | Cricetulus | 1 | 2007 | 114 | 0.060 |
Why?
| | Atrophy | 1 | 2007 | 199 | 0.060 |
Why?
| | Androstadienes | 1 | 2007 | 75 | 0.060 |
Why?
| | Hydrogen Peroxide | 2 | 2020 | 332 | 0.060 |
Why?
| | Cytokines | 3 | 2019 | 2043 | 0.060 |
Why?
| | Cell Respiration | 2 | 2017 | 105 | 0.060 |
Why?
| | Receptors, GABA-A | 1 | 2008 | 137 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2007 | 272 | 0.060 |
Why?
| | Phosphatidylcholines | 2 | 2017 | 130 | 0.060 |
Why?
| | Translocation, Genetic | 1 | 2007 | 118 | 0.060 |
Why?
| | Aeromonas | 1 | 2006 | 1 | 0.060 |
Why?
| | Gait | 1 | 2009 | 312 | 0.060 |
Why?
| | Models, Structural | 1 | 2006 | 41 | 0.060 |
Why?
| | Muscle Contraction | 1 | 2009 | 429 | 0.060 |
Why?
| | Corticosterone | 1 | 2007 | 242 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2007 | 247 | 0.060 |
Why?
| | Lung | 1 | 2019 | 4084 | 0.060 |
Why?
| | Spectrophotometry, Infrared | 1 | 2006 | 54 | 0.060 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2006 | 20 | 0.060 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 122 | 0.060 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 145 | 0.060 |
Why?
| | Receptor, Muscarinic M2 | 1 | 2006 | 10 | 0.060 |
Why?
| | Biological Transport | 1 | 2007 | 416 | 0.060 |
Why?
| | Receptors, Presynaptic | 1 | 2006 | 10 | 0.060 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2006 | 29 | 0.060 |
Why?
| | Receptors, Glutamate | 1 | 2006 | 26 | 0.060 |
Why?
| | Smad Proteins | 1 | 2006 | 43 | 0.060 |
Why?
| | Sulfonylurea Receptors | 1 | 2005 | 4 | 0.060 |
Why?
| | Hydrogen | 1 | 2006 | 73 | 0.060 |
Why?
| | Hydroxy Acids | 1 | 2005 | 4 | 0.060 |
Why?
| | Organic Chemicals | 1 | 2007 | 126 | 0.060 |
Why?
| | Receptors, Drug | 1 | 2005 | 10 | 0.060 |
Why?
| | Sex Factors | 2 | 2013 | 2103 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 559 | 0.060 |
Why?
| | Ligands | 1 | 2008 | 661 | 0.060 |
Why?
| | Decanoic Acids | 1 | 2005 | 12 | 0.060 |
Why?
| | Mass Spectrometry | 2 | 2020 | 741 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2007 | 237 | 0.060 |
Why?
| | Spleen | 1 | 2007 | 507 | 0.060 |
Why?
| | Isoenzymes | 2 | 2005 | 297 | 0.060 |
Why?
| | Hemiplegia | 1 | 2005 | 20 | 0.060 |
Why?
| | Cardiography, Impedance | 1 | 2004 | 9 | 0.060 |
Why?
| | Lower Extremity | 2 | 2009 | 440 | 0.050 |
Why?
| | Ventricular Pressure | 2 | 2016 | 52 | 0.050 |
Why?
| | Imidazoles | 1 | 2006 | 246 | 0.050 |
Why?
| | Cell Line | 1 | 2010 | 2821 | 0.050 |
Why?
| | Cholinergic Agonists | 1 | 2004 | 8 | 0.050 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2004 | 6 | 0.050 |
Why?
| | Carbachol | 1 | 2004 | 17 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 372 | 0.050 |
Why?
| | Young Adult | 3 | 2019 | 14092 | 0.050 |
Why?
| | Physical Fitness | 1 | 2006 | 207 | 0.050 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 491 | 0.050 |
Why?
| | Colforsin | 1 | 2004 | 47 | 0.050 |
Why?
| | Treatment Outcome | 6 | 2023 | 11713 | 0.050 |
Why?
| | Cardiomegaly | 1 | 2006 | 174 | 0.050 |
Why?
| | Electric Impedance | 1 | 2004 | 110 | 0.050 |
Why?
| | Spinal Cord | 1 | 2007 | 383 | 0.050 |
Why?
| | Blotting, Western | 2 | 2003 | 1160 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2008 | 733 | 0.050 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2004 | 91 | 0.050 |
Why?
| | Extracellular Space | 1 | 2004 | 119 | 0.050 |
Why?
| | Weight-Bearing | 1 | 2005 | 181 | 0.050 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 125 | 0.050 |
Why?
| | Merozoite Surface Protein 1 | 1 | 2023 | 4 | 0.050 |
Why?
| | Drug Synergism | 1 | 2004 | 352 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2011 | 8265 | 0.050 |
Why?
| | Autografts | 1 | 2023 | 55 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2024 | 212 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2023 | 92 | 0.050 |
Why?
| | Models, Statistical | 1 | 2007 | 675 | 0.050 |
Why?
| | Anura | 1 | 2003 | 45 | 0.050 |
Why?
| | Epinephrine | 1 | 2023 | 154 | 0.050 |
Why?
| | Australia | 1 | 2023 | 287 | 0.050 |
Why?
| | Oocytes | 1 | 2003 | 178 | 0.050 |
Why?
| | Receptor, Muscarinic M1 | 1 | 2002 | 4 | 0.050 |
Why?
| | Hyperalgesia | 1 | 2003 | 131 | 0.050 |
Why?
| | Heart Ventricles | 1 | 2007 | 750 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2023 | 296 | 0.050 |
Why?
| | Phospholipase C beta | 1 | 2002 | 30 | 0.050 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2002 | 29 | 0.050 |
Why?
| | TRPC Cation Channels | 1 | 2002 | 14 | 0.050 |
Why?
| | Diglycerides | 1 | 2002 | 59 | 0.040 |
Why?
| | Calmodulin | 1 | 2002 | 69 | 0.040 |
Why?
| | Tibia | 1 | 2003 | 175 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2006 | 770 | 0.040 |
Why?
| | Glycopeptides | 1 | 2002 | 44 | 0.040 |
Why?
| | Glucose | 2 | 2017 | 1033 | 0.040 |
Why?
| | Succinates | 1 | 2021 | 23 | 0.040 |
Why?
| | Hippocampus | 1 | 2007 | 964 | 0.040 |
Why?
| | Models, Molecular | 1 | 2006 | 1607 | 0.040 |
Why?
| | Myocardial Reperfusion | 1 | 2021 | 57 | 0.040 |
Why?
| | Pain Measurement | 1 | 2003 | 553 | 0.040 |
Why?
| | Linezolid | 1 | 2020 | 25 | 0.040 |
Why?
| | Cytoskeleton | 1 | 2002 | 195 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 363 | 0.040 |
Why?
| | Wound Healing | 1 | 2023 | 345 | 0.040 |
Why?
| | Reperfusion | 1 | 2020 | 54 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2005 | 1098 | 0.040 |
Why?
| | Biosensing Techniques | 1 | 2002 | 138 | 0.040 |
Why?
| | Hydrogels | 1 | 2007 | 699 | 0.040 |
Why?
| | Toxicity Tests | 1 | 2020 | 34 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2003 | 440 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 228 | 0.040 |
Why?
| | Ventricular Remodeling | 2 | 2015 | 275 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2019 | 113 | 0.040 |
Why?
| | Actins | 1 | 2002 | 421 | 0.040 |
Why?
| | CA3 Region, Hippocampal | 1 | 2019 | 6 | 0.040 |
Why?
| | Indoles | 1 | 2003 | 500 | 0.040 |
Why?
| | Photogrammetry | 1 | 2019 | 12 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2019 | 221 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 154 | 0.040 |
Why?
| | Computer-Aided Design | 1 | 2019 | 40 | 0.040 |
Why?
| | Pyridines | 1 | 2003 | 601 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2019 | 45 | 0.040 |
Why?
| | Drug Design | 1 | 2020 | 174 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2003 | 778 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 2018 | 15 | 0.040 |
Why?
| | Cytochromes c | 1 | 2018 | 52 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 2032 | 0.030 |
Why?
| | Delphi Technique | 1 | 2020 | 329 | 0.030 |
Why?
| | Multimodal Imaging | 1 | 2019 | 129 | 0.030 |
Why?
| | Lysophospholipids | 1 | 2018 | 78 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 475 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 541 | 0.030 |
Why?
| | Eicosapentaenoic Acid | 1 | 2017 | 36 | 0.030 |
Why?
| | Biomimetic Materials | 1 | 2018 | 76 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 334 | 0.030 |
Why?
| | Melanocytes | 1 | 2017 | 65 | 0.030 |
Why?
| | Electron Transport Complex III | 1 | 2017 | 18 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2017 | 96 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 172 | 0.030 |
Why?
| | Societies, Medical | 1 | 2021 | 890 | 0.030 |
Why?
| | Acyltransferases | 1 | 2017 | 78 | 0.030 |
Why?
| | Epidermis | 1 | 2017 | 157 | 0.030 |
Why?
| | Physical Endurance | 2 | 2009 | 274 | 0.030 |
Why?
| | Enzymes | 1 | 2017 | 65 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1762 | 0.030 |
Why?
| | Blood Pressure | 1 | 2003 | 1763 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2019 | 305 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 401 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 209 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2009 | 1300 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2003 | 1314 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2015 | 26 | 0.030 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 32 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2015 | 130 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1416 | 0.030 |
Why?
| | Brain | 1 | 2007 | 2929 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 679 | 0.030 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2005 | 72 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 61 | 0.020 |
Why?
| | Thromboxanes | 1 | 2012 | 13 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 547 | 0.020 |
Why?
| | Collagen | 1 | 2015 | 450 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 76 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 74 | 0.020 |
Why?
| | Aging | 1 | 2003 | 1935 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 447 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2012 | 82 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 461 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2012 | 181 | 0.020 |
Why?
| | Clonazepam | 1 | 2010 | 4 | 0.020 |
Why?
| | Ouabain | 1 | 2010 | 18 | 0.020 |
Why?
| | Thiazepines | 1 | 2010 | 6 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 2033 | 0.020 |
Why?
| | Eating | 1 | 2013 | 388 | 0.020 |
Why?
| | Isoproterenol | 1 | 2010 | 95 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 628 | 0.020 |
Why?
| | NAD | 1 | 2010 | 82 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2005 | 1699 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 557 | 0.020 |
Why?
| | Perfusion | 1 | 2010 | 248 | 0.020 |
Why?
| | Transcription Factors | 1 | 2017 | 1726 | 0.020 |
Why?
| | Patient Selection | 1 | 2013 | 721 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2741 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2013 | 643 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4248 | 0.020 |
Why?
| | California | 1 | 2009 | 471 | 0.020 |
Why?
| | Zirconium | 1 | 2007 | 11 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2007 | 104 | 0.020 |
Why?
| | Torque | 1 | 2007 | 81 | 0.020 |
Why?
| | Lead | 1 | 2007 | 70 | 0.020 |
Why?
| | Neoplasms | 1 | 2003 | 2860 | 0.020 |
Why?
| | Rats, Inbred SHR | 1 | 2007 | 36 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2007 | 76 | 0.020 |
Why?
| | Resistance Training | 1 | 2009 | 185 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2007 | 318 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 427 | 0.020 |
Why?
| | Research Design | 1 | 2013 | 1128 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2006 | 11 | 0.020 |
Why?
| | Materials Testing | 1 | 2007 | 349 | 0.010 |
Why?
| | Ventricular Function | 1 | 2006 | 54 | 0.010 |
Why?
| | Oxotremorine | 1 | 2005 | 1 | 0.010 |
Why?
| | Neuronal Calcium-Sensor Proteins | 1 | 2005 | 1 | 0.010 |
Why?
| | Estrenes | 1 | 2005 | 13 | 0.010 |
Why?
| | Phospholipase C delta | 1 | 2005 | 5 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2006 | 284 | 0.010 |
Why?
| | Pyrrolidinones | 1 | 2005 | 29 | 0.010 |
Why?
| | Neuropeptides | 1 | 2005 | 74 | 0.010 |
Why?
| | DNA Primers | 1 | 2006 | 507 | 0.010 |
Why?
| | Muscle Strength | 1 | 2007 | 330 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 650 | 0.010 |
Why?
| | Electric Stimulation | 1 | 2005 | 276 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2005 | 312 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2005 | 220 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 401 | 0.010 |
Why?
| | Rats, Inbred BN | 1 | 2003 | 54 | 0.010 |
Why?
| | United States | 1 | 2021 | 15979 | 0.010 |
Why?
| | Green Fluorescent Proteins | 1 | 2005 | 402 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2005 | 330 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 2003 | 268 | 0.010 |
Why?
| | Caffeine | 1 | 2003 | 74 | 0.010 |
Why?
| | Echocardiography | 1 | 2006 | 644 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2171 | 0.010 |
Why?
| | Pacemaker, Artificial | 1 | 2003 | 126 | 0.010 |
Why?
| | Databases, Genetic | 1 | 2003 | 247 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1809 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 749 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 688 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1990 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22370 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1259 | 0.010 |
Why?
| | Prospective Studies | 1 | 2009 | 7972 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1839 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3408 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 4293 | 0.010 |
Why?
|
|
Brown's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|